Real-world use of Dalbavancin for vascular graft and Endograft infections - 22/07/26
, M. Ascione b, a, 1, M. Carnevalini a, F. Faccenna b, F. Miceli b, A. Di Girolamo b, L. Di Marzo b, C. Mastroianni a, W. Mansour b, A. Oliva aAbstract |
Objective |
To describe the clinical effectiveness and safety of dalbavancin (DAL) for the treatment of Vascular Graft and Endograft Infections (VGEI).
Methods |
A retrospective, single-center observational study was conducted at a tertiary-care university hospital in Rome from January 2020 to December 2024, including all consecutive patients diagnosed with VGEI who received at least one dose of DAL. Cases were identified through the hospital electronic medical record database. VGEIs were diagnosed using MAGIC criteria. Primary outcomes were clinical and radiological response at the end of treatment (EOT) and at six-month follow-up.
Results |
Thirteen patients were included (median age: 76 years; 92% of males; median Charlson Comorbidity Index 5). Aortic vessels were involved in 61.5% of cases, peripheral vessel in 38.5%. Microbiological identification was achieved in 84.6% of cases, with Staphylococcus aureus (MSSA and MRSA) being the most frequent pathogen. Surgical explant was performed in 53.8% of patients, predominantly for peripheral VGEIs. DAL was used to facilitate early discharge (69.2%) or as suppressive antibiotic therapy (30.8%). No adverse events related to DAL were reported. Clinical success was achieved in 84.6% of patients at EOT and maintained in 61.5% at six-month follow-up.
Conclusion |
DAL appears to be an effective and well-tolerated option for the management of VGEI, particularly in frail patients or those not eligible for surgery, both to facilitate early discharge and as long-term suppressive antibiotic therapy (SAT). Further prospective studies are needed to confirm these findings.
Le texte complet de cet article est disponible en PDF.Graphical abstract |
Highlights |
• | Real-world experience with dalbavancin for vascular graft/endograft infections is reported. |
• | Dalbavancin facilitated hospital discharge in 69.2% of cases and served as suppressive therapy in 30.8%. |
• | Clinical success was achieved in 84.6% of patients at the end of treatment, maintained in 61.5% at six-month follow-up. |
• | No dalbavancin-related adverse events were observed, even with prolonged use. |
• | Dalbavancin appeared effective and well tolerated, particularly in frail patients unfit for surgery. |
Keywords : Device-associated infection, Vascular Graft and Endograft Infection, Suppressive antibiotic therapy, Long-acting antibiotics, Dalbavancin
Plan
Vol 56 - N° 5
Article 105313- juillet 2026 Retour au numéro
Article précédent
- Treatment duration of community-acquired pneumonia due to Legionella pneumophila: where do we stand?
- Aurélien Dinh, Michelle Saliba, Laurence Maulin, Yves Welker
- The environmental impacts and costs of cefotaxime versus ceftriaxone: An example drawn from Paris hospitals
- Etienne Raphaël, Samantha Huynh, Virginie Siorat, Aurélien Sokal, Damien Blez, Albane Degrassat-Théas, Mathilde Réveillon-Istin, Agnès Lefort, Raphaël Lepeule
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?